EyePoint Pharmaceuticals Receives $9.5 Million in Upfront Cash from Ocumension Therapeutics Under Expanded License Agreements
WATERTOWN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing […]